Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf your Mounjaro supply has been interrupted, or you're wondering whether another medicine could step in, the honest answer is: there is no direct like-for-like replacement. Tirzepatide is the only dual GIP and GLP-1 receptor agonist licensed for weight management in the UK, which sets it apart from every other option currently available. That distinction matters clinically, and any switch is a decision for a prescriber — not something to arrange on your own. Here's what the evidence and UK guidance actually say about your options.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Strictly speaking, no. Mounjaro's active ingredient, tirzepatide, works on two separate hormone receptors simultaneously, GIP and GLP-1. That dual action influences appetite, gastric emptying and blood-sugar regulation in a way that single-pathway medicines don't replicate. Every other weight-loss injection currently available in the UK targets GLP-1 alone.
That said, if your supply is interrupted, you're not without options. Wegovy (semaglutide 2.4mg, or now up to 7.2mg following MHRA approval of a higher-dose pen in April 2026) is the closest alternative, and it has a strong evidence base of its own, the STEP 1 trial recorded around 15% average body-weight reduction over 68 weeks at 2.4mg, as published in the New England Journal of Medicine. The gap between the two medicines has narrowed at higher semaglutide doses, but tirzepatide still produced greater average weight loss in the SURMOUNT-5 head-to-head trial. Whether the difference matters for you individually is a clinical question, not a statistical one.
If you're researching tirzepatide more broadly, the tirzepatide overview on our site covers the mechanism, licensing and evidence in full.
This is the question most people really want answered, and the truthful reply is: it depends on when you switch, how long you've been on your current dose, and the new medicine's titration schedule.
GLP-1 medicines generally require a gradual dose escalation, partly to limit side effects, partly because the therapeutic effect builds over weeks. Switching mid-treatment means your body goes through that adjustment period again. Some people tolerate it well; others find the restart harder than the original. There is no published evidence specifically on switching from tirzepatide to semaglutide partway through treatment, so a prescriber is working from clinical judgement and your individual history rather than a fixed protocol.
Weight regain during a gap is also a real concern. The biological drivers of appetite return quickly when treatment stops, which is why continuity matters so much. If you're trying to avoid a break in treatment, sourcing Mounjaro reliably from a regulated UK pharmacy may resolve the problem before a switch becomes necessary. It's worth exploring supply before making a clinical change.
For practical questions about how to approach a switch, our FAQs cover common scenarios, and our clinical team is reachable through our contact page if you're already a patient.
No. This comes up often, and the answer is unambiguous. No supplement, herbal product or over-the-counter tablet replicates the mechanism or the clinical evidence behind tirzepatide or semaglutide. Products marketed as Mounjaro supplements are not substitutes, they don't interact with GIP or GLP-1 receptors, and claims to the contrary aren't supported by any UK-approved evidence. The MHRA regulates medicines for exactly this reason: the bar for proving a treatment works and is safe is high, and no supplement has cleared it for meaningful weight loss. If you see something marketed as a 'natural replacement' for Mounjaro, treat that claim with real scepticism.
The NHS overview of tirzepatide on the NHS medicines pages is worth reading if you want a clear, plain-language account of what the medicine actually does, useful context if you're evaluating alternatives.
First, don't stop without a plan. Contact your prescribing service as soon as you know there's a gap coming. Most shortages, if they exist at all, are dose-specific and short-lived, a brief wait at your current dose is very different from stopping treatment entirely.
If you're ordering privately, timing matters more than people expect. Ordering before a bank holiday weekend, payday rush, or school-holiday period means you're less likely to hit a processing queue. At nume, orders placed before midday on a working day go through same-day clinical review, with dispatch and free next-working-day DPD delivery for approved patients, so the lead time is genuinely short when you plan ahead. If you want to keep track of your injections between orders, our Mounjaro stickers can help you log each dose clearly on your pen.
If a switch really is necessary, your prescriber will advise on how to bridge the gap safely. That might mean moving to Wegovy, adjusting your dose timing, or holding briefly and restarting. It is not a decision to make by reading forum posts or ordering something unverified online, and if you have ever wondered whether Mounjaro is a placebo, our dedicated page explains the clinical evidence and why the weight loss it produces is very much real. Counterfeit pens are a documented risk in the UK, and buying Mounjaro online safely means using a pharmacy you can verify on the GPhC register.
If you'd like to talk through your situation with a prescriber, start a free consultation and one of our team will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.